Knowing that none of the randomized phase III trials in HER2 negative breast cancer comparing bevacizumab plus chemotherapy with chemotherapy alone nor meta-analyses of them showed any effect on overall survival [4,5,6,7,27,42,43,44], such a survival difference would, if confirmed, certainly influence clinical practice. The gene discussed is ERBB2; the disease is breast cancer.